The observation of aerobic glycolysis by tumor cells in 1924 by Otto Warburg, and subsequent innovation of imaging glucose uptake by tumors in patients with PET-CT, has incited a renewed interest in the altered metabolism of tumors. As tumors grow in situ, a fraction of it is further away from their blood supply, leading to decreased oxygen concentrations (hypoxia), which induces the hypoxia response pathways of HIF1α, mTOR, and UPR. In normal tissues, these responses mitigate hypoxic stress and induce neoangiogenesis. In tumors, these pathways are dysregulated and lead to decreased perfusion and exacerbation of hypoxia as a result of immature and chaotic blood vessels. Hypoxia selects for a glycolytic phenotype and resultant acidification of the tumor microenvironment, facilitated by upregulation of proton transporters. Acidification selects for enhanced metastatic potential and reduced drug efficacy through ion trapping. In this review, we provide a comprehensive summary of preclinical and clinical drugs under development for targeting aerobic glycolysis, acidosis, hypoxia and hypoxia response pathways. Hypoxia and acidosis can be manipulated, providing further therapeutic benefit for cancers that feature these common phenotypes.
INTRODUCTION
Otto Warburg first described an increased rate of aerobic glycolysis followed by lactic acid fermentation in cancer cells in 1924, later termed the Warburg Effect (Warburg et al., 1927) . Almost a century of research has confirmed Warburg's initial observation, solidifying increased glycolytic flux as a common cancer phenotype (Hanahan & Weinberg, 2011) . Increased expression of glycolytic genes are observed in w70% of human cancers (Altenberg & Greulich, 2004) . Warburg had hypothesized the metabolic shift away from oxidative phosphorylation was due to mitochondrial dysfunction, yet this has not been substantiated (Warburg, 1956) . While interest in cancer metabolism peaked in the middle part of the twentieth century, interest waned with the advent of molecular biological techniques in the 1970s. In 1976, Sidney Weinhouse famously declared that "Since our perspectives have broadened over the years, the burning issues of glycolysis and respiration in cancer now flicker only dimly" (Weinhouse, 1976) . The development of 18 Ffluorodeoxyglucose ( 18 FDG)-PET imaging to visualize increased glucose uptake in tumors and metastasis has rekindled interest in cancer metabolism, and is commonly used clinically for diagnosis and disease monitoring (Kelloff et al., 2005 ). An important characteristic of the tumor microenvironment commonly found in cancers and a selection force for the glycolytic phenotype is hypoxia. Tumor hypoxia can be transient or chronic either spatially or temporally, leading to significant heterogeneity and stress. Hypoxia is a challenge clinically due to its correlation with poor prognosis and association with resistance to chemotherapy and radiation therapy (Dewhirst et al., 2008) .
We have previously proposed a series of microenvironment barriers that must be overcome for a tumor to develop during carcinogenesis Gillies et al., 2008) . As carcinogenesis begins, inadequate growth promotion and loss of contact with the basement membrane are encountered first, which are commonly overcome by developing an insensitivity to antigrowth signals and self-sufficiency in growth signalsdtwo Hallmarks of Cancer defined by Hanahan and Weinberg (Hanahan & Weinberg, 2011) . As in situ cancers grow further away from the vasculature and beyond the diffusion limit of oxygen, the available concentration of oxygen is reduced, leading to hypoxic conditions. In locally invasive and metastatic lesions, hypoxia is exacerbated when neoangiogenesis creates a chaotic and immature vasculature network resulting in inconsistent oxygen delivery (Gillies et al., 1999) . Cancer cells upregulate glycolysis to maintain energy production in the absence of oxygen (The Pasteur Effect), eventually becoming the preferred energy production pathway even during reoxygenation (The Warburg Effect). Aerobic glycolysis is accompanied by lactic acid fermentation, creating significant amounts of free protons (H þ ) which are shuttled to the extracellular tumor microenvironment to maintain intracellular pH (pHi) at physiological levels. Increasing amounts of H þ being pumped into the extracellular space creates an acidic microenvironment, which is known to select for cells with enhanced metastatic potential as well as provide resistance to chemotherapy (Moellering et al., 2008; Raghunand & Gillies, 2000; Rofstad et al., 2006; Schlappack et al., 1991; Wojtkowiak et al., 2011) . The tumor microenvironmental characteristics described earlier are heterogeneous within a tumor and are found in virtually all human solid tumors. Furthermore, while there are common metabolic phenotypes, these can arise by a multitude of genetic changes, otherwise known as the "functional equivalence principle" . Hence, targeting the causes and consequences of the tumor microenvironment is an effective way to reach a large population of patients and inhibition can potentially overcome tumor growth and metastasis. In this review, we describe techniques used clinically for imaging the tumor metabolic microenvironment, as well as developmental drugs to target various aspects of tumor metabolism. Finally, we detail methods that are currently being investigated preclinically and clinically to manipulate the tumor microenvironment for therapeutic benefit.
IMAGING THE TUMOR MICROENVIRONMENT
Imaging approaches to characterize the metabolic microenvironment of tumors provide useful biomarkers for diagnosis and monitoring therapy response. In the future, it is expected that imaging will be able to be the most beneficial therapy for a particular patient. In the next section, we will detail some of the most common MRS, MRI, and PET clinical imaging methods of imaging tumor pH and hypoxia (for more detailed review see Hashim et al., 2011; Pacheco-Torres et al., 2011) .
MRS and MRI
Magnetic resonance spectroscopy (MRS) imaging techniques depend on differences in chemical shifts of either endogenous or exogenous nuclear MRactive compounds based on pH-dependent or -independent resonances (Gillies & Morse, 2005) . pH measurements with 31 P-MRS can compare the chemical shifts of endogenous inorganic phosphate (P i ) to measure pHi with that of exogenous 3-aminopropyl phosphonate (3-APP) to measure extracellular pH (pHe) (Shepherd & Kahn, 1999) . Hyperpolarized 13 C bicarbonate enters into a Henderson-Hasselbalch equilibrium which can be used to spatially image a tumor pHe (Gallagher et al., 2008) . While imaging with hyperpolarized 13 C bicarbonate is more sensitive than imaging with 3-APP, the main limitation lies with the rapid (within 1-2 min) decrease in hyperpolarization of bicarbonate. An alternative magnetic resonance imaging (MRI) technique is to use pH-dependent relaxation, such as gadolinium-DOTA-4AmP 5À in mixture with dysprosium-DOTP 5- (Garcia-Martin et al., 2006; Raghunand et al., 2003) .
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PET
Positron emission tomography (PET) imaging of tumors with 18 F-2-deoxyglucose (FDG) has had the most impact clinically in diagnosis, analysis of cancer staging, and monitoring response to therapy (Kelloff et al., 2005) . FDG is taken up via glucose transporters (GLUT1 or GLUT3) and is phosphorylated by hexokinase, effectively trapping FDG in the cytoplasm unable to be further metabolized. PET imaging measures the annihilation reaction between a positron released from FDG during decay with a neighboring electron. Computer analysis of the signals received from annihilation reactions can reconstruct the location and quantity of positron-emitting radionucleotides, giving an accurate description of a tumor and metastasis.
A number of PET tracers for hypoxia have been developed. 18 F-fluoromisonidazole (FMISO) has been the most widely developed and used to image hypoxia in tumors (Valk et al., 1992) . FMISO is a nitroimidazole derivative which enters cells through passive diffusion and undergoes a reduction reaction. Once reduced, FMISO becomes trapped and concentrated in cells in the absence of oxygen, allowing for PET imaging to detect regions of hypoxia within a tumor. FMISO has been studied extensively, and is available through an IND for detection of hypoxia in patients on clinical trials. Clinical studies suggest that uptake of FMISO by a tumor is predictive of its resistance to treatment radiation therapy (Thorwarth et al., 2006) .
Electron paramagnetic resonance imaging (EPRI), an imaging technique similar to nuclear magnetic resonance, measures the interactions between molecular oxygen and a nontoxic stable radical tracer (Matsumoto et al., 2010) . EPRI is able to measure the partial oxygen pressure (pO 2 ) of tumors without radioisotopes and is capable of measuring dynamic pO 2 changes, allowing for the measurement of intermittent hypoxia in tumors (Bennewith et al., 2002) . Although it has only been applied preclinically, EPRI is able to measure tumor hypoxia quickly generating 3-dimensional pO 2 maps from data obtained during imaging.
TARGETING GLUCOSE METABOLISM
Aerobic glycolysis has long been known to be a common hallmark of solid tumors. This metabolic switch has been proposed to provide an advantage to growing tumors by allowing adaptation to low oxygen environments. This leads to increased acidification of the local tumor microenvironment, allowing for evasion of the immune system and increased metastatic potential Kroemer & Pouyssegur, 2008) . In the next section, we describe drugs that are in preclinical or clinical studies that target glucose metabolism of tumors (Fig. 4.1) .
Targeting Glucose Transporters
Glucose, a major carbon source for cells, is a 6-carbon ring structure converted to pyruvate canonically along the Embden-Meyerhof glycolytic pathway. Entry of glucose into cells occurs by facilitated diffusion through a family of 14 membrane-bound proteins called glucose transporters (GLUTs). GLUT1, the founding member of the GLUT family, was isolated from erythrocytes in 1977 (Kasahara & Hinkle, 1977) . Upregulation of GLUT1 and GLUT3 expression has been described in many cancers, and may be a key step in tumor progression. Increased expression of GLUTs correlate with poor prognosis and short survival of patients with ovarian, Figure 4 .1 Inhibitors of glucose metabolism. The figure depicts the glycolytic pathway from glucose entry into cells through production of pyruvate, which is converted either to lactate or to acetyl-coA for entry into the TCA cycle. Movement of metabolic intermediates through the pathway is designated by arrows. Enzymes in the glycolytic pathway are placed next to the arrow leading from their substrate to their product. Inhibitors of glycolytic enzymes or glucose transporters appear in boxes. For color version of this figure, the reader is referred to the online version of this book.
breast, and squamous cell carcinomas (Ayala et al., 2010; Cantuaria et al., 2001; Pinheiro et al., 2011) . GLUT1 (K m ¼ 6.9 mM) and GLUT3 (K m ¼ 1.8 mM) each have a high affinity for glucose, and are thought to be the main transport mechanisms for glucose into cells (Burant & Bell, 1992; Gould et al., 1991; Shepherd & Kahn, 1999) . Importantly, Hatanaka showed in 1974 that glucose uptake by cells is a rate-limiting step in glycolysis. Subsequent work by other groups determined that transformed cells with increased expression of GLUTs at the plasma membrane is a strong independent prognostic indicator for FDG uptake and glucose consumption (Birnbaum et al., 1987; Bos et al., 2002; Flier et al., 1987; Hatanaka, 1974) .
Increased expression of GLUT1 and GLUT3 during tumor progression allows for unregulated metabolism of glucose, making it an intriguing therapeutic target. Recent research described the cytotoxic and chemosensitizing properties of anti-GLUT1 antibodies in numerous lung and breast cancer cell lines reconfirming the importance of glucose uptake for survival (Rastogi et al., 2007) . Decades of research have resulted in the discovery of many other GLUT inhibitors, including Cytochalasin B and select tyrosine kinase inhibitors (Taverna & Langdon, 1973; Vera et al., 2001) .
High-throughput screening for drugs capable of sensitizing cells that evade FAS ligand-induced apoptosis have identified fasentin, a small molecule inhibitor that binds to the intracellular channel of GLUT1, reducing glucose transport (Schimmer et al., 2006) . Further studies uncovered altered expression of genes involved in glucose metabolism following treatment of FAS-resistant prostate and leukemia cells with fasentin and FAS ligand (Wood et al., 2008) . Ultimately, fasentin alone was unable to induce cell death in FAS-ligand resistant cells, despite a rapid, albeit, partial reduction in glucose uptake following fasentin treatment.
Renal cell carcinoma (RCC), known for harboring inactivating mutations in the von Hippel-Lindau (VHL) ubiquitin ligase gene, was identified as a candidate for chemical synthetic lethality screening for GLUT inhibitors (Chan et al., 2011) . VHL mutations often coincide with a reorganized metabolic profile, wherein the tumor becomes highly glycolytic and relies on high levels of GLUT1 expression. One class of compounds, led by STF-31, caused necrotic cell death in RCC cells lacking functional VHL. In silico modeling revealed a potential docking site for STF-31 located in the central channel of GLUT1, and further functional studies confirmed inhibition of GLUT1 by STF-31. FDG-PET scans confirm reduced glucose uptake in RCC tumors treated with STF-31, corresponding with retarded tumor growth. Lack of toxicities resulting from treatment with STF-31 encourages further research into its therapeutic potential and widespread efficacy in other tumors overexpressing GLUT1.
Targeting Hexokinase
As glucose enters the cystol, hexokinase phosphorylates the sixth carbon, effectively trapping glucose intracellularly and priming it for catabolism. Hexokinase-2 is frequently overexpressed in cancers, overcoming silencing methylation found on its promoter in normal tissues (Goel et al., 2003) . Expression of hexokinase is transcriptionally regulated by both p53 and hypoxia-inducible factor 1a (HIF1a) (Mathupala et al., 1997) . Glucose analogs, specifically 2-deoxyglucose, can be radiolabeled to image tumors with increased glucose uptake ( 18 FDG), and have also been studied as inhibitors of glycolysis (Kurtoglu et al., 2007; Lampidis et al., 2006) . These analogs enter cells normally through GLUT1 or GLUT3 transporters and are phosphorylated by hexokinase. As with glucose, the 6-phospho form of these analogs are unable to exit cells, and are feedback inhibitors of hexokinase activity. However, unlike glucose, the phosphorylated glucose analogs are unable to be rapidly catabolized through the remainder of the glycolytic pathway, that is, phosphofructokinase, and can build up to high levels intracellularly, where they prevent further glucose metabolism. Although there have been some successes using deoxyglucose in vitro and in animal models as a glycolytic inhibitor, clinical successes have not extended past utilization as an imaging contrast agent to visualize tumors or as a radio-sensitizing agent (Ramirez-Peinado et al., 2011; Song et al., 1976) .
3-bromopyruvate (3-BrPA) has been identified as a potent inhibitor of glycolysis through its promiscuous inhibition of hexokinase-2 as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 3-BrPA has been widely studied as an alkylating agent, but its first anticancer properties were identified in 2001 as an inhibitor of hexokinase-2 (Ko et al., 2001; Meloche et al., 1972 ). Selectivity appears to depend on its uptake by overexpressed monocarboxylate transporter, SLC5A8 (Thangaraju et al., 2009) . In addition to its use as a single agent, recent research has focused on combining 3-BrPA with other chemotherapies to overcome ATP-requiring multidrug resistance (MDR) mechanisms. Nakano et al. used 3-BrPA to sensitize MDRexpressing tumors to daunorubicin or doxorubicin treatment (Nakano et al., 2011) . Similar work by Zhou et al. confirms that intracellular ATP is essential for drug resistance, and that disruption of cellular energy levels through inhibition of hexokinase-2 by 3-BrPA resensitized MDR cells to therapy (Zhou et al., 2012) .
Lonidamine was first identified as an inhibitor of aerobic glycolysis through inhibition of hexokinase-2 in tumor cells in 1981 (Floridi & Lehninger, 1983; Floridi et al., 1981) . As with 3-BrPA, inhibition of hexokinase-2 by lonidamine induced apoptosis (Brawer, 2005) . Lonidamine acts as a single agent and has been extensively studied as a treatment for MDR (Li et al., 2002; Ravagnan et al., 1999) . Already approved for use as an anticancer chemotherapy in Europe, phase II clinical trials began in the United States in 2005 treating patients with benign prostatic hyperplasia (BPH) (Brawer, 2005; Ditonno et al., 2005) . Despite reports of some cancer patients receiving 40 times the dose than patients in the US trial, and indications that prostate volumes were reduced during treatment, the US phase II trial was terminated due to liver toxicities and no subsequent trials have begun (Ditonno et al., 2005; Milane et al., 2011b) . In an effort to harness the therapeutic efficacy of lonidamine against MDR and reduce toxicities due to dosage, Milane et al. have developed epidermal growth factor receptor (EGFR)-targeted nanoparticles encapsulating lonidamine and paclitaxel (Milane et al., 2011a,b) . Orthotopic MDR-positive breast cancer xenografts treated with targeted drug-containing nanoparticles showed reduced tumor growth compared to treatment with blank nanoparticles. Transient weight losses were observed in all groups. Liver toxicities were highest in animals treated with soluble paclitaxel alone or soluble paclitaxel þ lonidamine, and were less severe when drugs were bound to nanoparticles. Hematologic analyses also revealed reduced toxicity following treatment with drug combinations encapsulated within nanoparticles. Overall, lonidamine is a promising hexokinase-2 inhibitor that may show clinical benefit either alone or in combination with other chemotherapies.
Targeting Phosphofructokinases
Phosphofructokinase-1 (PFK-1) catalyzes the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate in a rate-limiting step in the glycolytic pathway. Regulation of PFK-1 activity is reduced as a result of oncogene activation, such as Ras or Src, through elevated levels of fructose-2,6-bisphosphateda physiologic activator of PFK-1 (Bosca et al., 1986; Kole et al., 1991) . Phosphofructokinase-2 (PFK-2), as well as the p53 target TIGAR, is a regulator of the steady-state level of intracellular fructose-2,6-bisphosphate, and the PFKFB3 isozyme has been identified to be overexpressed in leukemias and solid tumors (Atsumi et al., 2002; Bensaad et al., 2006) . Small molecule inhibitors targeting the substrate-binding domain of PFKFB3 have been identified as antineoplastic agents (Clem et al., 2008) . In vitro inhibition of recombinant PFKFB3 revealed 3PO (3-(3-Pyridinyl)-1-(4-Pyridinyl)-2-Propen-1-one) as a lead compound that inhibits PFKFB3 but does not affect activity of PFK-1. 3PO was further shown to inhibit normal cell cycling in several solid tumor and hematologic cell lines further inhibiting tumor growth in xenograft models of lung, breast, and leukemia by suppression of glycolytic flux (Clem et al., 2008) .
To improve upon clinical limitations of 3PO, such as solubility and high preclinical doses, Akter et al. has engineered nanoparticle drug delivery systems for 3PO (Akter et al., 2011 (Akter et al., , 2012 . Encapsulating 3PO within a hydrophilic shell through conjugation to block copolymers improved 3PO bioavailability. 3PO conjugated block copolymers were also engineered with a hydrazone bond that is cleaved in acidic conditions (pH < 7.0) to preferentially target acidic tumor microenvironments. In vitro experiments with 3PO containing micelles resulted in significant cell death across several cell lines providing encouragement for future work in preclinical models.
In a separate study, N4A and YN1 were identified to be competitive inhibitors of PFKFB3 (Seo et al., 2011) . While treatment of cells with these novel compounds resulted in decreased glycolytic flux followed by cell death, selectivity of the drugs was not ideal, and further optimization of the drug scaffold is currently underway.
Targeting Pyruvate Kinase M2
Pyruvate kinase (PK) catalyzes the transfer of a phosphate from phosphoenolpyruvate to ADP in the final step of aerobic glycolysis, resulting in one molecule each of ATP and pyruvate. Of the four pyruvate kinase isoforms, PKM1 is expressed in most tissues. PKM2 is a splice variant of PKM1 that is primarily expressed in embryonic development, but is also reported to be the main isoform expressed in tumors (Christofk et al., 2008) . PKM2 expression has been associated with the Warburg Effect, carcinogenesis, and tumor growth. Due to increased expression of PKM2, cancer patients typically have higher levels of PKM2 in plasma and saliva, and this is being investigated in a clinical trial to determine if salivary levels of PKM2 can be used as a biomarker for malignancy (NCT01130584).
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TT-232 (TLN-232/CAP-232) is a somatostatin structural analog that has been shown to significantly reduce tumor growth in murine models, and has entered clinical trials for refractory metastatic RCC and melanoma (NCT00422786 and NCT00735332). TT-232 has antiinflammatory effects through its interaction with somatostatin receptor 4 (SSTR4), a G proteincoupled receptor, and antitumor effects mediated through its inhibition of PKM2 (Elekes et al., 2008; Stetak et al., 2007) . Unlike somatostatin, TT-232 is able to exhibit antitumor effects without the antisecretory activity that is required for somatostatin's efficacy in neuroendocrine tumors and pancreatitis (Greenberg et al., 2000) . In addition to inhibition of PKM2, treatment of cells with TT-232 inhibits proliferation, induces cell cycle arrest, and initiates apoptosis Vantus et al., 2001) . Phase I clinical trials of TT-232 were successfully completed without significant adverse events, allowing entry into phase II trials.
Targeting Pyruvate Dehydrogenase Kinase
Following the conversion of phosphoenolpyruvate to pyruvate by PK, further oxidation of pyruvate is enabled by mitochondrial pyruvate dehydrogenase (PDH), which catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA, which can then enter the tricarboxylic acid (TCA) cycle. PDH is negatively regulated at three serine phosphorylation sites by pyruvate dehydrogenase kinase (PDK), which shifts glucose from oxidative to glycolytic metabolism (Holness & Sugden, 2003) .
Dichloroacetate (DCA) has been used clinically over the past several decades for the treatment of lactic acidosis and mitochondrial disorders (Stacpoole et al., 1988) . DCA is an inexpensive, orally available drug that targets PDK (Bowker-Kinley et al., 1998; Knoechel et al., 2006; Stacpoole, 1989) , and has recently been shown to have anticancer effects both in vitro and in vivo (Bonnet et al., 2007; Wong et al., 2008; Xie et al., 2011) . The Michelakis group hypothesized that inhibition of PDK with DCA could shift glucose metabolism from glycolytic to oxidative, eliminating excessive lactic acid production observed in cancer cells (Bonnet et al., 2007) . Indeed, treatment of lung, glioblastoma, and breast cancer cells reversed cell metabolism from glycolytic to oxidative; and in doing so increased ROS production, decreased mitochondrial membrane potential, and sensitized cells to apoptosis. In vivo rodent studies demonstrated the antitumor properties of DCA by reducing overall tumor volumes and inducing apoptosis in a lung cancer xenograft model (Bonnet et al., 2007) . Further preclinical studies have shown DCA to have similar proapoptotic effects on endometrial cancer cells as well as sensitizing prostate cancer cells to radiation therapy Wong et al., 2008) . Numerous clinical trials are currently recruiting, or underway, to administer DCA as a single agent, or in combination with other chemotherapies or radiation, in a wide range of cancers. The first published data from clinical trials with DCA as an anticancer therapy was recently published (Michelakis et al., 2010) . Resected glioblastoma tissue from 49 patients treated with DCA confirmed mitochondrial depolarization in vivo. Five patients with either newly diagnosed or recurrent glioblastoma were placed on a treatment regimen of DCA with standard therapies, temozolomide (TMZ) and radiation therapy, after surgical tumor debulking. During a 15-month follow-up, toxicities were moderate, with peripheral neuropathy being the only toxicity noted with w80% of patients remaining clinically stable 15 month after the onset of therapy.
Targeting Lactate Dehydrogenase (LDH)
Lactate dehydrogenase (LDH) catalyzes the interconversion of pyruvate and lactate. LDH is a tetrameric protein made from two different (heart and muscle) subunits. LDH5 (a.k.a. LDH-A or M 4 ) is usually expressed in muscle tissue and has a low K m for pyruvate, while LDH1 (a.k.a. H 4 ) is more ubiquitously expressed and has a lower K m for lactate. During the redox reaction of pyruvate to lactate, NADH is oxidized to NAD þ , replenishing intracellular levels of NAD þ and allowing glycolysis to become self-sufficient. LDH5 subunits are transcriptionally regulated by HIF1a and hence levels of LDH5 are increased in HIF1a-positive cancers (Firth et al., 1995; Semenza et al., 1996) . Recently, LDH5 has been shown to be important for tumor initiation, although the exact mechanism is currently unclear (Fantin et al., 2006; Goldman et al., 1964; Xie et al., 2009 ). Gossypol, a cotton seed extract, has been studied as an antifertility drug that inhibits sperm LDH, and further experimentation has revealed cross inhibition of gossypol analogs to LDH5 (Kim et al., 2009 ). More recent gossypol analog studies focusing on 8-deoxyhemigossylic derivates that target the NADH and pyruvate binding sites of LDH identified 3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid, or FX11, as a preferential inhibitor of LDH5 (Yu et al., 2001) . Treatment of human lymphoma cells, P493, with FX11 correlated with knockdown of LDH5 by siRNA by increasing oxygen consumption, ROS production, decreasing ATP levels, and cell death (Le et al., 2010) . Similar results were
Targeting the Metabolic Microenvironment of Tumors observed in RCC and breast cell lines, with the sensitivity to FX11 being highest in cells with a more glycolytic phenotype. In vivo studies also indicated that FX11 inhibits both carcinogenesis and tumor progression of lymphoma and pancreatic tumors (Le et al., 2010) . It was notable that these treatments were not myelosuppressive or toxic, despite the presence of LDH-A in normal tissues. Although a promising candidate drug to target the glycolytic phenotype of tumors, FX11 is not yet in clinical trials.
The most recent research for novel LDH5 inhibitors began in an attempt to fabricate a drug suitable for entry into the clinic. From this research, a series of N-hydroxyindole-based inhibitors were generated to have specificity for LDH5 over LDH1 (Granchi et al., 2011) . In vitro experiments showed promising K i values in the low micromolar range for some of the compounds synthesized. Additionally, cellular assays resulted in reduced lactate production and retarded cellular proliferation. Virtual screening of the National Cancer Institute (NCI) Diversity Set by another group identified galloflavin as a novel LDH inhibitor (Kim et al., 2009) . Galloflavin was further characterized and shown to bind preferentially to free enzyme without blocking either the pyruvate or NADH binding sites. Enzymatic assays using purified LDH1 and LDH5 showed that galloflavin acts as an inhibitor of both isoforms. Cellular assays confirmed in vivo activity of galloflavin with reduced lactate production, a reduction of cellular ATP levels, and decreased cellular proliferation. Preliminary murine experiments suggest that galloflavin could be a well tolerated drug that should be developed further.
TARGETING HYPOXIA
Hypoxia is another common phenotype of solid tumors. As tumors grow, proangiogenic factors stimulate new vessel growth within a tumor. However, these new vessels tend to be immature and chaotic, and hence lead to poor perfusion (Gillies et al., 1999) . Tumors found to contain hypoxic regions typically respond poorly to therapy in the clinic (Dewhirst et al., 2008) . Hypoxia can be difficult to target due to its spatial and temporal heterogeneity within tumors and the fact that hypoxic volumes are the most poorly perfused. Nonetheless, successful approaches to target hypoxia have been developed, and some of these are in clinical trials. These approaches can be broadly described as (1) targeting hypoxia response pathways; (2) drugs that require hypoxia for their activity and thus efficacy and (3) methods to manipulate hypoxia to our advantage to increase efficacy of hypoxia-activated prodrugs (Table 4 .1).
Targeting Hypoxia Response Pathways
Tumors typically have lower oxygen concentrations (pO 2 ) than levels detected in normal tissue (Hockel & Vaupel, 2001) . As a tumor grows outward, away from blood vessels, the ability to receive oxygen from diffusion through tissue diminishes quickly leading to diffusion-limited (or chronic) hypoxia. Additionally, perfusion-limited (or acute) hypoxia can (Jaakkola et al., 2001; Ohh et al., 2000) . In response to hypoxia, HIF1a is not degraded and the resulting stabilized protein will heterodimerize with HIF1b (a.k.a. the aryl hydrocarbon receptor nuclear translocator, ARNT) and activate promoters containing hypoxia response elements (HREs). Transcriptional targets of HIF1a can be found in glycolytic, angiogenic, survival, and migration pathways (Semenza, 2003) . Constitutive HIF1a stabilization has been observed in many cancers and is correlated with aggressive disease, poor prognosis, and drug resistance, making HIF1a an attractive drug target (Birner et al., 2000; Bos et al., 2003; Giatromanolaki et al., 2001; Osada et al., 2007) . This is an active area of research and there are numerous investigational drugs aimed at inhibiting HIF1a with a number of approaches: for example, targeting HIF1a mRNA expression, protein translation, protein stability, and transcriptional activity. Following, we illustrate some of these approaches. More exhaustive discussion of this subject can be found at (Vaupel, 2004) . Topotecan is an FDA approved drug that is indicated for ovarian, cervical cancers, and small cell lung carcinoma. The primary mechanism of action is through inhibition of topoisomerase I which induces genotoxic stress through DNA double strand breaks (Hsiang et al., 1985) . Screening of the NCI Diversity Set of chemical compounds for small molecule inhibitors led to the discovery of a second mechanism of topotecan activity through inhibition of HIF1a expression (Rapisarda et al., 2002) . Further topotecan studies confirmed inhibition of HIF1a expression, concluding that translation of HIF1a is inhibited in a topoisomerase 1-dependent mechanism by topotecan (Rapisarda & Uranchimeg et al., 2004a) . Tumor xenograft models treated with topotecan have decreased HIF1a levels, diminished angiogenesis, and reduced tumor growth (Rapisarda & Zalek et al., 2004b) . Furthermore, patients treated with topotecan had low to undetectable levels of HIFa in tumor biopsies, correlating with decreased levels of vascular endothelial growth factor (VEGF) and GLUT1 (Kummar et al., 2011) .
Seven of 10 patients treated with topotecan to receive dynamic contrast enhanced (DCE)-MRI exhibited decreased blood flow and permeability through their tumors after one treatment.
Abolishing expression of HIF1a has been shown to be an effective way to inhibit tumor growth, inspiring the development of methods to target mRNA expression of HIF1a as an alternative to targeting HIF1a stability. An antisense oligonucleotide designed to inhibit HIF1a expression has moved into clinical trials . EZN-2968 was developed by Enzon Pharmaceuticals, Inc. using locked nucleic acid (LNA) oligonucleotide technology to reduce HIF1a expression (Greenberger et al., 2008; Vester & Wengel, 2004) . EZN-2968 was confirmed to selectively inhibit HIF1a mRNA expression in vitro, resulting in a lasting decrease in HIF1a protein levels, followed by a reduction in expression of HIF1a target genes. EZN-2968 also showed activity in a tumor xenograft model by repressing tumor growth. Phase 1 clinical studies treating hematologic patients with EZN-2968 have recently concluded (NCT00466583) and have been followed by a pilot trial that is currently recruiting patients with liver metastasis (NCT01120288).
PX-478 is an orally available small molecule that has been shown to inhibit HIF1a activity by reducing HIF1a levels (Welsh et al., 2004) . Tumor xenograft experiments using a variety of tumor cell lines showed that treatment with PX-478 reduced tumor growth or tumor regression which correlated with decreased levels of HIF1a and its target genes GLUT1 and VEGF. The half life of PX-478 in murine plasma is short at 50 min, although concentrations capable of inhibiting HIF1a expression can be found for 8 h. Imaging of tumor xenografts with DCE and diffusion-weighted (DW)-MRI showed that treatment with PX-478 reduced tumor blood vessel permeability within 2 h of treatment and returned to normal 48 h after treatment (Jordan et al., 2005) . Mechanistic studies have revealed that PX-478 may have multiple mechanisms of action in the inhibition of HIF1a by hindering both transcription and stability of HIF1a protein (Koh et al., 2008) . PX-478 can also contribute to clinical efficacy by acting as a radiosensitizer in prostate cancer cell lines and in in vivo tumor models (Palayoor et al., 2008; Schwartz et al., 2009) . Recently, phase I clinical trials investigating the safety and preliminary efficacy of PX-478 in patients with advanced solid tumor or lymphomas were completed (NCT00522652). Results from the phase I trial, presented at the 2010 ASCO Annual meeting, showed stable disease (SD) in w40% of participants with mild toxicities (Tibes et al., 2010) .
Targeting mTOR
The mammalian target of rapamycin (mTOR) is a kinase that is activated during cell stresses, including nutrient and energy depletion, triggering a signaling cascade regulating metabolism and many cell survival mechanisms (Dazert & Hall, 2011; Jung et al., 2010) . mTORC1, a subunit of a complex nucleated by mTOR, has been shown to be important for tumorigenesis following activation of AKT (Skeen et al., 2006) . Exposure to hypoxia in normal cells promotes activation of the tuberous sclerosis protein 1 complex (TSC1/2), which in turn negatively regulates the mTOR complex . Additional evidence indicates that inhibition of the mTOR complex due to hypoxia can be accomplished through interaction with promyelocytic leukemia (PML) tumor suppressor or disruption of mTORC1 binding to RHEB (Bernardi et al., 2006; Li et al., 2007) . It is hypothesized that hypoxiamediated inhibition of mTOR is a selective mechanism for mutations that are beneficial for cell growth in hostile environments (Graeber et al., 1996) . Alternatively, constitutively active mTOR has been observed in advanced breast cancer. In addition, loss of mTOR repressors, such as PTEN and TSC1/2, can result in unregulated mTOR activity (Connolly et al., 2006; Kaper et al., 2006) . While the exact role mTOR plays in carcinogenesis is not fully understood, mTOR inhibitors have been successful on the bench, and have moved into the clinic.
Rapamycin, a metabolite isolated from bacteria, was first identified in the 1970s to be a powerful antifungal drug (Vezina et al., 1975) . Rapamycin was quickly determined to have antitumor activity, and was discovered to selectively target mTOR allosterically in the early 1990s (Heitman et al., 1991; Houchens et al., 1983) . Rapamycin also has potent immunosuppressive activity and is approved for transplant patients to prevent organ rejection as well as antirestenosis after heart surgery due to its antiangiogenic properties, but is not an approved medication for the treatment of cancer. Analogs of rapamycin, or "rapalogs," are constantly being designed to be more specific to mTOR and have better pharmacologic properties and have been successful in the clinic. Currently, CCI779, or temsirolimus, is approved for treatment of RCC and mantle cell lymphoma, and is being investigated clinically for the treatment of other cancers, such as leukemia, non-small cell lung cancer (NSCLC), and breast cancer (Hess et al., 2009; Hudes et al., 2007; Rini, 2008) . RAD001, or everolimus, has been approved for RCC and pancreatic neuroendocrine tumors, as well as an antirejection medication following organ transplant (Gabardi & Baroletti, 2010; Motzer et al., 2008) . In addition to single agent drugs, rapalogs are being investigated in coordination with drugs that target other signaling pathways to improve efficacy, such as PI3K or AKT (Ayral-Kaloustian et al., 2010; Cirstea et al., 2010; Ikezoe et al., 2007) .
The antidiabetic drug metformin and its analogs buformin and phenformin have recently been identified as having potential anticancer activity. Metformin reduces blood glucose levels through decreasing hepatic gluconeogenesis and activation of AMPK (AMP-activated protein kinase) and is commonly used clinically for the treatment of type 2 diabetes (Hundal et al., 2000; Stumvoll et al., 1995; Zhou et al., 2001) . AMPK can regulate activity of mTOR through activation of TSC1/2 (Inoki et al., 2003) . Studies of diabetic patients receiving metformin revealed significantly reduced cancer risk compared to cohorts receiving other diabetic medications (Bowker et al., 2006; Evans et al., 2005) . In vitro studies later confirmed that metformin represses growth of breast cancer cells through an AMPK-dependent signaling and inhibition of mTOR mechanism (Dowling et al., 2007; Zakikhani et al., 2006) . Metformin treatment seems to inhibit other cellular processes such as the cell cycle through reduction of cyclin D1 and diminishing the transcription of GRP78, an estrogen receptor chaperone protein that is elevated in cancers and involved in Unfolded Protein Response (UPR) signaling (Ben Sahra et al., 2008; Saito et al., 2009) . Metformin is currently being investigated clinically to determine if it is best used as a treatment or a preventative medication.
Targeting UPR
Hypoxia inhibits the ability of the endoplasmic reticulum (ER) to properly fold and organize proteins. The UPR is activated in the ER under hypoxia stress, which functions to maintain ER homeostasis or initiate apoptosis. Three proteins found at the ER membrane, PERK (PKR-like ER kinase), IRE1 (inositol requiring 1), and ATF6 (activating transcription factor 6), act independently to signal stresses leading to UPR activation (Koumenis et al., 2002) . Response by the UPR to hypoxia is important for tumor growth, and aberrant UPR signaling due to the absence of PERK or IRE1 results in increased regions of hypoxia and reduced growth rates (Bi et al., 2005; Romero-Ramirez et al., 2004) . Activation of the UPR response results in both reduction of translation and inhibition of protein maturation pathways as well as a detoxification process known as ER-associated degradation Targeting the Metabolic Microenvironment of Tumors (ERAD) and induction of autophagy (Rouschop et al., 2010) . In addition to activation of UPR in response to hypoxia, other cellular stresses often found in solid tumors can lead to UPR activation. Such stresses include calcium homeostasis, redox status, and glucose depravation, making UPR an important cellular response mechanism in cancer, and also an attractive pathway to target clinically.
The ERAD response to cellular stresses is activated by the UPR and results in priming misfolded proteins to be shuttled out to the cytoplasm for proteasomal degradation (Travers et al., 2000) . Blocking the ERAD response through proteasome inhibitors like bortezomib (PS-341) has been a successful strategy for tumors with high ER stress such as multiple myeloma (Lee et al., 2003; Nawrocki et al., 2005) . Recent research suggests that hypoxia sensitizes cells to ER stress resulting from bortezomib treatment, leading authors to suggest pairing bortezomib with normoxia targeting drugs to improve therapeutic response (Fels et al., 2008) . Such combinations have been investigated in murine models, and have shown to repress tumor growth when bortezomib was used in coordination with a HDAC6 specific inhibitor, ACY-1215, in a multiple myeloma model (Santo et al., 2012) . Clinical trials are also ongoing, investigating the efficacy of combining bortezomib treatment with other chemotherapies, such as mitoxantrone (topoisomerase II inhibitor), mapatumumab (antibody specific for TRAIL death receptor), and vorinostat (HDAC inhibitor).
IRE1 has two enzymatic domains, a kinase domain and an endonuclease domain (Dong et al., 2001; Nock et al., 2001) . Crystal structures have shown that IRE1 dimerizes in a juxtaposed configuration that allows for autophosphorylation resulting in increased endonuclease activity (Han et al., 2009; Korennykh et al., 2009) . Screening for potential inhibitors of IRE1 using a cell-based reporter system identified STF-083010 (Papandreou et al., 2011) . Treatment of multiple myeloma cells with ER stresses resulted in mRNA cleavage of XBP1 by IRE1, which was abrogated with treatment of STF-083010 (Back et al., 2006) . STF-083010 was shown to selectively inhibit the endonuclease activity of IRE1 without affecting kinase activity. Although in vivo antitumorigenic responses were observed, more research will need to be performed to optimize an IRE1 inhibitor using STF-083010 as a scaffold. Another high-throughput screening search found salicylaldimine analogs to be inhibitors of IRE1 (Volkmann et al., 2011) . Similar to STF-083010, salicaldehydes inhibit IRE1 endonuclease activity in vitro and in vivo, increasing the interest to develop more potent and selective inhibitors targeting IRE1.
Using Hypoxia to Our Advantage
Use of Bioreductive Drugs
Bioreductive prodrugs are a class of drugs that are inert in tissues with normal pO 2 but are able to undergo chemical reduction in tissues with severe hypoxia to release cytotoxic warheads, selectively targeting cancer cells within hypoxic regions. In general, there are five different chemical scaffolds that have been used to generate bioreductive prodrugs (nitro groups, quinones, aromatic N-oxides, aliphatic N-oxides, and transition metals), all of which are able to be reduced in the absence of oxygen. One of the earliest reports of the use of bioreductive quinones to selectively target hypoxia is the use of mitomycin C in the 1960s (Iyer & Szybalski, 1964; Schwartz et al., 1963) . During the last half century, bioreductive drugs scaffolds have been improved upon making them more selective and potent in hypoxic tumors.
Tirapazamine, or TPZ, is one of the most advanced bioreductive drugs through the clinical trials process. TPZ is built off of an aromatic N-oxide bioreductive scaffold (Zeman et al., 1986) . During hypoxia, TPZ undergoes an intracellular one-electron reduction to a radical anion, then further converted to either a hydroxyl radical or an oxidizing radical, ultimately resulting in DNA damage Baker et al., 1988; Zagorevskii et al., 2003) . TPZ creates DNA interstrand cross-links which stall replication forks and induce DNA breaks that require homologous recombination repair . TPZ has been extensively studied clinically in combination with cisplatin and radiation in patients with squamous cell carcinoma, head and neck cancer, and lung cancer with moderate to inconclusive results (Le et al., 2004; Rischin et al., 2005; Rischin et al., 2010; von Pawel et al., 2000) . Further analysis showed that TPZ was being metabolized too quickly, and was not effectively penetrating tumor tissues (Hicks et al., 1998; Kyle & Minchinton, 1999) . Consequently, TPZ analogs are currently being developed with the goal of improving drug solubility, cytotoxicity, selectivity, and tissue penetration characteristics (Hicks et al., 2010) .
TH-302 is built upon a scaffold of a 2-nitroimidazole and is a nitrogen mustard prodrug that is selectively reduced under hypoxia (<0.5% O 2 ) (Duan et al., 2008) . As TH-302 is reduced, the prodrug splits and releases its Targeting the Metabolic Microenvironment of Tumors cytotoxic warhead, bromo-isophosphoramide mustard (Br-IPM). As Br-IPM is released into hypoxic tissue, it cross-links with DNA, killing cells in the hypoxia compartment as well as neighboring cells with its bystander effect (Sun et al., 2012; Zhang et al., 2005) . TH-302 was shown to have efficacy in vitro and in vivo in a wide subset of cancer cell lines and xenografts and was further found to have favorable drug-like properties and pharmacokinetic profiles (Duan et al., 2008; Hu et al., 2010; Meng et al., 2012) . TH-302 entered phase I clinical trials as a single agent drug in patients with advanced solid tumors and has also been tested in combination with doxorubicin in patients with advanced soft tissue sarcoma, gemcitabine in patients with pancreatic cancer; docetaxel for patients with prostate or lung cancers (Ganjoo et al., 2011; Weiss et al., 2011) . TH-302 was generally well tolerated, but some patients experienced skin and mucosal dose-limiting toxicities. Recently, phase I/II clinical trials of TH-302 as a single agent concluded with SD or better detected across a number of cancer types. Current clinical trials are investigating the efficacy of TH-302 as a single agent or in combination therapy for cancers, including melanoma, multiple myeloma, RCC, pancreatic carcinoma, and phase III trials have begun in patients with sarcoma.
Banoxantrone, or AQ4N, is a N-oxide bioreductive prodrug that was developed to selectively target hypoxic regions of tumors (Smith et al., 1997) . The reduction under hypoxia releases a cytotoxic alkylaminoanthraquinone metabolite (AQ4) which induces DNA damage through inhibition of topoisomerase II. AQ4N has been shown to be efficacious in murine models of breast cancer when combined with chemotherapy or radiation therapy (Gallagher et al., 2001; Patterson et al., 2000; Williams et al., 2009) . Phase I clinical trials have investigated the activity of AQ4N either as a single agent or in combination with radiation therapy (Papadopoulos et al., 2008; Steward et al., 2007) . AQ4N was well tolerated by patients and is now being tested in clinical trials to evaluate the efficacy of AQ4N (NCT00394628, NCT00109356, and NCT00090727).
Two other bioreductive drugs, apaziquone (E09) and PR-104, have been successful on the bench top and have moved into clinical studies (Hendricksen et al., 2009; McKeage et al., 2011) . While bioreductive drugs have been especially successful in preclinical studies, and have shown some success in the clinic, no bioreductive prodrug has been approved by the FDA to date. Current research is aimed at improving bioreductive prodrug selectivity, stability, and cytotoxicity. Additionally, research is ongoing to develop bioreductive prodrugs that are non-genotoxic and instead target other cellular processes. For example, 2-nitroimidazole-5-ylmethyl is a 2-nitroimidazole that releases 5-bromoisoquinoline after reduction, targeting poly(ADP-ribose) polymerase 1 (PARP1) (Parveen et al., 1999) .
Manipulating Hypoxia
While the data from hypoxia activated prodrugs (HAPs) in the clinic are promising, it can be reasoned that they may be more efficacious if tumor hypoxia can be selectively and transiently increased at the time of treatment. Thus, inducing hypoxia in tumors can be an efficient way of increasing the efficacy of drugs that target hypoxia. There are a number of mechanisms available with which to exacerbate tumor hypoxia selectively, including metabolically (e.g., pyruvate or DCA), or by reducing oxygen delivery (e.g., antiangiogenic agents or vasodilators).
It has recently been shown that tumor hypoxia can be increased following intravenous injection of pyruvate , whose mechanism of action may involve inducing cells to increase respiration (Kauppinen & Nicholls, 1986) . EPRI, a spectroscopic imaging technique that measures in vivo oxygen concentrations, of tumors in mice following an intravenous injection of hyperpolarized 13 C pyruvate revealed a significant decrease in tumor oxygenation that reached a maximum at 1 h, and returned to normal within 5 h . Knowledge of a tumors oxygenation status is important for treatment plans, as pyruvate-induced hypoxia reduced the ability of radiotherapy to kill cancer cells even after tumor oxygenation had returned to normal levels. DCA, an inhibitor of PDK, has also been reported to initiate a metabolic switch in cancer cells from glycolysis to oxidative phosphorylation (Xie et al., 2011) . Induction of oxidative phosphorylation by DCA increased reactive oxygen species, pH, and apoptotic proteins in HeLa cells. Additionally, the metabolic switch observed after DCA treatment correlated with an increased sensitivity of HeLa cells to cisplatin, suggesting that manipulation of a tumors metabolism may be therapeutically successful.
Tumor oxygenation can also be manipulated by controlling oxygen delivery with antiangiogenic or antivascular agents. Angiogenesis is a common phenotype ("Hallmark") of cancer that is regulated by HIF1a signaling (Hanahan & Weinberg, 2011) . Tumors support an induction of angiogenesis by producing angiogenic growth factors such as VEGF and platelet-derived growth factor (PDGF). Several antiangiogenic inhibitors that target the immature angiogenic vasculature have been approved, Targeting the Metabolic Microenvironment of Tumors including sorafenib, a VEGFR and PDGFR inhibitor, avastin (bevacizumab), an antibody targeting VEGF, and sunitinib, a VEGFR and PDGFR inhibitor (Chung et al., 2010) . Although resistance to antiangiogenic drugs has become a major obstacle in clinical cancer treatment (Mitchell & Bryan, 2010) , their use to acutely increase hypoxia in combination with HAPs has not yet been published. Alternatively, there are agents, such as combretastatin, that will target mature vessels, and these are also known to increase tumor hypoxia (Dachs et al., 2006) . Another characteristic of the immature tumor vasculature is a lack of tone. Thus, vasodilators, such as hydralazine, induce a systemic drop in blood pressure, which is not matched by the tumor vasculature, causing a transient decrease in perfusion within the tumor (Sonveaux, 2008a) . This "steal" phenomenon has been demonstrated using Doppler Ultrasound to measure decreased tumor blood flow (Horsman et al., 1992) . The decrease in perfusion leads to increases in acidosis and hypoxia; both have been shown using pH electrodes or MRS, for acidosis and pO 2 electrodes for hypoxia (Adachi & Tannock, 1999; Belfi et al., 1994; Nordsmark et al., 1996; Okunieff et al., 1988) .
TARGETING ACIDOSIS
The microenvironment of solid tumors is known to be more acidic (pH 6.5-6.9) than the physiological pH of normal tissue (pH 7.2-7.5), which can be attributed to a tumor's increased glycolytic flux and poor vasculature perfusion (Griffiths, 1991; Wike-Hooley et al., 1984) . Acidic microenvironments have been shown to increase the invasiveness of a tumor, leading to increased metastasis (Moellering et al., 2008; Rofstad, 2000; Rofstad et al., 2006) . In this section, we will describe drugs that target acidosis in tumors and systematic approaches to reduce acidosis in the tumor microenvironment (Fig. 4.2) .
Targeting Proton Transport
Metabolically produced hydrogen ions (acid) can be exported from cells by a variety of mechanisms including, inter alia, sodium-hydrogen exchange (NHE), anion exchangers (AEs), vacuolar ATPases (V-ATPases), and membrane-bound carbonic anhydrases (CAs) (Neri & Supuran, 2011) . NHE and AE are ubiquitously expressed and have proven to be poor anticancer drug targets, either through inefficacy or through toxicity, and these have been reviewed (Grinstein et al., 1989) . Following, we will discuss some of the newer, less well-explored members of this class of transporters.
CAs are metalloenzymes that catalyze the interconversion of carbon dioxide and water to bicarbonate and protons. Mammalian carbonic anhydrases (a-CAs) can be cystolic, mitochondrial, secreted, or membranebound. The primary function of mammalian CAs is to maintain the acidbase balance of cells, tissue, and blood. As aerobic glycolysis becomes the primary means of energy production for a tumor cell, the ability to regulate physiological pHi becomes paramount to maintain cellular processes such as proliferation as well as inhibition of apoptosis (Shen et al., 2006; Tiseo et al., 2009) . CAIX and CAXII are two transmembrane CAs that have been identified to be associated with tumor progression and metastasis (Aulitzky et al., 1989; Fantin et al., 2006) . As a transcriptional target of HIF1a, CAIX expression is upregulated in hypoxic tissue and has been shown to be a poor prognostic marker in several cancer types, including breast cancer (Lou et al., 2011) . CAXII is also overexpressed in tumors and is associated with disease progression and response to therapy (Supuran, 2008; Tureci et al., 1998) . As carbon dioxide is hydrated, HCO 3 À is moved intracellularly to maintain pHi while protons are pumped into the extracellular environment of a tumor, Figure 4 .2 Proteins that contribute to tumor acidosis and their inhibitors. The figure depicts proteins and transporters that contribute to extracellular acidosis in a tumor due to increased lactate production from increased glycolytic flux. Included are CAIX and CAXII, carbonic anhydrases that catalyze the interconversion between carbon dioxide and water to bicarbonate and protons; and V-ATPases and MCTs, which allow transport of H þ into the extracellular environment. Inhibitors of the proteins that contribute to tumor acidosis appear in boxes. For color version of this figure, the reader is referred to the online version of this book.
Targeting the Metabolic Microenvironment of Tumors decreasing the pHe (Shepherd & Kahn, 1999) promoting an aggressive metastatic environment (Jaakkola et al., 2001; Xie et al., 2009 ). Members of a-CA require zinc for activity, making them susceptible to inhibition by sulfonamides, which coordinates with the zinc ion found in the active sites of CAs. Sulfonamide analogs, such as topiramate, sulpiride, and valdecoxib, have been shown to potently inhibit CAXII, while zonisamide has been identified to be an effective inhibitor of CAIX (Greenberger et al., 2008; Li et al., 2005) . Perhaps the most studied sulfonamide analog, indisulam, has high affinity for CAIX and CAXII, in addition to seven other CAs (Greenberger et al., 2008; Li et al., 2005) . Indisulam inhibits CAIX in nanomolar quantities and shows efficacy against tumor xenografts in vivo. In addition to CAIX inhibition, indisulam induced sequelae, such as disruption of the G1/G2 phases of the cell cycle and expression changes of genes related to cell adhesion, cell signaling, and altered glucose metabolism (Owa et al., 1999; Rapisarda et al., 2002; Rapisarda & Zalek et al., 2004b; Vester & Wengel, 2004) .
Clinical trials for the treatment of solid tumors with indisulam have been ongoing for the past decade. Five phase I clinical trials have been conducted focusing on optimizing the dosing regimen of indisulam to patients with solid tumors (Birner et al., 2000; Bos et al., 2003; Giatromanolaki et al., 2001; Kummar et al., 2011; Welsh et al., 2004) . Fatigue and mucositis were noted as adverse events during the trial, and reversible neutropenia and thrombocytopenia were dose-limiting toxicities. Phase II trials have been completed on patients with platinum-pretreated NSCLC in a multicenter study (Jordan et al., 2005) . While some patients experienced a positive response to indisulam, the effect was not long term. Objective responses to indisulam therapy were not achieved during this trial, which may be attributed to inherent difficulties of being a second-line therapy to platinum-pretreated NSCLC (Koh et al., 2008) . Further trials are being conducted using indisulam as both a single agent and as combination therapy for different tumor types.
Another membrane-bound transporter involved with acidification of the tumor microenvironment is V-ATPase (Palayoor et al., 2008; Schwartz et al., 2009) . In tumor cells, V-ATPases can prevent intracellular acidification by transporting protons into lysosomal compartments that are released into extracellular space, or by directly pumping protons into the tumor microenvironment (Skeen et al., 2006) . In addition to promoting tumor metastasis by acidifying the tumor microenvironment, overexpression of V-ATPases following chemotherapy treatment appears to be a drug resistance mechanism (Li et al., 2007; Liu et al., 2006) . In 1988, bafilomycins were identified to be potent inhibitors of V-ATPases (Bernardi et al., 2006) . Since this discovery, several generations of V-ATPase inhibitors have been developed and investigated and can be classified into five families of V-ATPase inhibitors (Perez-Sayans et al., 2009 ). While targeting V-ATPases is desirable as an anticancer target to reduce metastatic potential and drug resistance, clinical relevance is unknown due to likely toxicities (Bi et al., 2005; Connolly et al., 2006; Kaper et al., 2006; Koumenis et al., 2002; Luciani et al., 2004) .
The monocarboxylate transporter 1, MCT1, a membrane-bound transporter is required for lactate (coupled with a proton) to move across the plasma membrane. MCT1 has been documented to have dysregulated expression in colorectal, breast, and cervical carcinomas (Asada et al., 2003; Pinheiro et al., 2008a; Pinheiro et al., 2008b) . Inhibition of MCT1 reduces intracellular pH and induces apoptosis, making it an attractive target for antitumorigenic therapy (Sonveaux et al., 2008b) . Several small molecule inhibitors of MCT1 have been identified including a-cyano-4-hydroxycinnamate (CHC), phloretin, and AR-C117977 (Bueno et al., 2007; Sonveaux et al., 2008b) . Currently, no MCT1 inhibitors are being investigated clinically.
Manipulating Tumor Microenvironment pH
Orally distributed systemic buffers have been shown to be an effective way to increase pHe of a tumor (Silva et al., 2009) . Continuous oral delivery of sodium bicarbonate to tumor bearing mice have been shown to increase selectively the pHe of a tumor and are effective at reducing the rate and size of metastasis, without changing the volume of the primary tumor (Jahde et al., 1990; Robey et al., 2009 ). In addition to reducing metastasis, buffering with sodium bicarbonate increased breast tumors sensitivity to doxorubicin and mitoxantrone, chemotherapies known to be ineffective in acidic tumor environments (Jahde et al., 1990; Raghunand et al., 2001; Wojtkowiak et al., 2011) . A similar reduction in metastasis was achieved using orally available imidazole(IEPA) or lysine buffers in murine experimental metastasis models (Ibrahim Hashim, Cornnell, et al., 2011; Ibrahim Hashim, Wojtkowiak, et al., 2011) .
MANIPULATING THE MICROENVIRONMENT FOR THERAPEUTIC BENEFIT
Combination therapy has been a long-standing strategy for the treatment of cancer patients. Drug resistance to single agent regimens is a major obstacle Targeting the Metabolic Microenvironment of Tumors in the clinic and combination therapy aims to target more of a heterogeneous tumor, reducing the ability of a tumor to develop resistance. The commonality of phenotypic characteristics of the tumor microenvironment between patients encourages the targeting of the microenvironment in combination with other cytotoxic chemotherapies. In the earlier sections, we detailed a number of approaches to target the tumor metabolic phenotype as well as describing strategies to manipulate hypoxia (exacerbation of hypoxia metabolically or by reducing oxygen delivery) and acidosis (buffer therapy) for therapeutic benefit. In this section, we will describe additional combination therapies that manipulate the metabolic or physiologic phenotype of cancers.
2DG, the glucose analog hexokinase inhibitor, has been unsuccessful as a single agent chemotherapy in the clinic, but has recently been of interest as a sensitizer of cancer cells to other chemotherapies or radiation therapy Lin et al., 2003; Simons et al., 2007; Zhang & Aft, 2009 ). Targeting metabolic pathways or DNA integrity through ionizing radiation (IR) or treatment with drugs like metformin in coordination with 2DG treatment can lead to significant antitumor effects (Ben Sahra et al., 2010; Cheong et al., 2011) . Clinical studies have verified that cotreatment of 2DG with IR is safe for patients, and reduced toxicity associated with IR in some patients (Mohanti et al., 1996; Singh et al., 2005) . Preclinical studies using 2DG as a sensitizer are promising; however, clinical studies investigating the efficacy need to be completed before 2DG sensitizing treatment becomes routine.
VEGF inhibitors, and antiangiogenic inhibitors in general, have similarly unintended effects on the tumor microenvironment, resulting in normalization of the tumor vasculature. Vascular normalization, first described by Rakesh K. Jain, is a maturation of existing immature vessels within a tumor when neoangiogenesis is inhibited (Goel et al., 2011; Jain, 2001 Jain, , 2005 . Vascular maturation results in better oxygen delivery and tumor perfusion, relieving interstitial tumor pressure which is hypothesized to provide better drug delivery to patients and reduce resistance to chemotherapy (Jain, 2005) . Treatment of tumor bearing mice with VEGF inhibitor DC101 resulted in tumor vascular remodeling, where vasculature became nonleaky and more organized . Further studies have been conducted to study the timing of vascular normalization with optimal sensitivity to radiation treatment Winkler et al., 2004) . Vascular normalization has been observed in patients with nonmetastatic rectal adenocarcinoma receiving bevacizumab (Willett et al., 2004 (Willett et al., , 2009 (Willett et al., , 2010 . 
Targeting the Metabolic Microenvironment of Tumors
Although tumor reduction was not observed, microvessel density and vascular permeability decreased and histological analysis confirmed the presence of mature vasculature within tumors. Preclinical and clinical studies have provided support for the vascular normalization hypothesis; however, more studies need to be completed to fully optimize the normalization window to improve efficacy of this treatment.
CONCLUSION
Initially a barrier during carcinogenesis, the tumor microenvironment during the later stages of carcinogenesis provides an advantage for a tumor to outcompete normal tissue, becoming more aggressive and metastatic. Additionally, common characteristics of a tumor microenvironment provide a haven of protection for a tumor against chemotherapies. The immature and chaotic vasculature that exacerbates hypoxia within a tumor also provides minimal perfusion through a tumor for effective drug therapy, and extracellular acidosis due to preferential metabolism through aerobic glycolysis creates an environment that effectively traps weakly basic drugs from moving intracellularly. Extensive research has been focused on targeting the tumor microenvironment, providing clinicians with chemotherapies that target the glycolytic pathway, acidosis, hypoxia, and hypoxia response pathways (Table 4 .2). Manipulation of the tumor microenvironment has been an effective strategy for the treatment of a wide range of patients and will continue to be an important area of drug discovery in the future.
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